More on ATX
Data
Financials
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $21.49 |
|
|||
| Open | $21.49 | ||||
| 52 Wk High | $22.62 | ||||
| 52 Wk Low | $10.75 | ||||
| Day High | $21.49 | ||||
| Day Low | $21.49 | ||||
| P/E | 42.98 | ||||
| EPS | $0.50 | ||||
| Volume | 47,094 | ||||
- Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
- OTC Markets Group Welcomes ATEX Resources Inc. to OTCQX
- Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
- Accent Trial Mature Data Presented at International Conference
- The Supply Gap No One's Talking About Is Repricing Copper Developers
- Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
- Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
- Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
- Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
Entities mentioned with ATX
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Trading Radar | View Related Stories »
- Deutsche Bank | View Related Stories »
- Raymond James | View Related Stories »
- Cowen & Co | View Related Stories »
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Show More...
